Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases

Histopathology

Volumn 63, Issue 2, 2013, Pages 234-241

  Boos, Laura A ^a,b   Dettmer, Matthias ^c   Schmitt, Anja ^c   Rudolph, Thomas ^c   Steinert, Hans ^b   Moch, Holger ^b   Sobrinho Simões, Manuel ^d   Komminoth, Paul ^e   Perren, Aurel ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF PORTO   (Portugal)

^e TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Angioinvasion; FISH; Outcome; PAX8 PPAR ; Prognosis; Thyroid carcinoma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR PAX8;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TISSUE MICROARRAY; TUMOR INVASION;

EID: 84880747218     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12150     Document Type: Article

References (37)

1. DeLellis RA, Williams ED. Thyroid and parathyroid tumours: introduction. In DeLellis RA, Lloyd RV, Heitz PU, Eng C eds. Pathology and genetics: tumours of endocrine organs. Lyon: IARC Press, 2004; 51-56.
2. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289; 1357-1360.
3. Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat. Genet. 1998; 19; 87-90.
4. DeLellis RA. Pathology and genetics of thyroid carcinoma. J. Surg. Oncol. 2006; 94; 662-669.
5. Sobrinho Simões M, Asa SL, Kroll TG et al. Follicular carcinoma. In DeLellis RA, Lloyd RV, Heitz PU, Eng C eds. Pathology and genetics: tumours of endocrine organs. Lyon: IARC Press, 2004; 67-72.
6. Aldred MA, Morrison C, Gimm O et al. Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 2003; 22; 3412-3416.
7. Nakabashi CC, Guimarães GS, Michaluart P Jr, Ward LS, Cerutti JM, Maciel RM. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma. Clin. Endocrinol. (Oxf). 2004; 61; 280-282.
8. Marques AR, Espadinha C, Catarino AL et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 2002; 87; 3947-3952.
9. Cheung L, Messina M, Gill A et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 2003; 88; 354-357.
10. Dwight T, Thoppe SR, Foukakis T et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 2003; 88; 4440-4445.
11. French CA, Alexander EK, Cibas ES et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 2003; 162; 1053-1060.
12. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 2002; 26; 1016-1023.
13. Nikiforova MN, Lynch RA, Biddinger PW et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003; 88; 2318-2326.
14. Lacroix L, Lazar V, Michiels S et al. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am. J. Pathol. 2005; 167; 223-231.
15. Algeciras-Schimnich A, Milosevic D, McIver B et al. Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin. Chem. 2010; 56; 391-398.
16. Klemke M, Drieschner N, Laabs A et al. On the prevalence of the PAX8-PPARγ fusion resulting from the chromosomal translocation t(2;3) (q13;p25) in adenomas of the thyroid. Cancer Genet. 2011; 204; 334-339.
17. Castro P, Roque L, Magalhães J, Sobrinho-Simões M. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int. J. Surg. Pathol. 2005; 13; 235-238.
18. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 2008; 21(Suppl. 2); 37-43.
19. Volante M, Collini P, Nikiforov YE et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 2007; 31; 1256-1264.
20. Dettmer M, Schmitt AM, Steinert H, Moch H, Komminoth P, Perren A. Poorly differentiated oncocytic thyroid carinoma-diagnostic implications and outcome. Histopathology 2012; 60; 1045-1051.
21. Dettmer M, Schmitt AM, Steinert H et al. Poorly differentiated thyroid carcinomas: how much poorly is needed? Am. J. Surg. Pathol. 2011; 35; 1866-1872.
22. Dancau AM, Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol. Biol. 2010; 576; 49-60.
23. Hibi Y, Nagaya T, Kambe F et al. Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA? Endocr. J. 2004; 51; 361-366.
24. Wolff DJ, Bagg A, Cooley LD et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J. Mol. Diagn. 2007; 9; 134-143.
25. Wiktor AE, Van Dyke DL, Stupca PJ et al. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet. Med. 2006; 8; 16-23.
26. Bhaijee F, Nikiforov YE. Molecular analysis of thyroid tumors. Endocr. Pathol. 2011; 22; 126-133.
27. Sahin M, Allard BL, Yates M et al. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J. Clin. Endocrinol. Metab. 2005; 90; 463-468.
28. Powell JG, Wang X, Allard BL et al. The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 2004; 23; 3634-3641.
29. Zhu Z, Ciampi R, Nikforova MN, Ghandi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 2006; 91; 3603-3610.
30. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 2011; 121; 3810-3818.
31. Nocito A, Bubendorf L, Tinner EM et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol. 2001; 194; 349-357.
32. Torhorst J, Bucher C, Kononen J et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 2001; 159; 2249-2256.
33. O'Grady A, Flahavan CM, Kay EW, Barrett HL, Leader MB. HER-2 analysis in tissue microarrays of archival human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. Appl. Immunohistochem. Mol. Morphol. 2003; 11; 177-182.
34. Ruiz C, Seibt S, Al Kuraya K et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int. J. Cancer 2006; 118; 2190-2194.
35. Moch H, Schraml P, Bubendorf L et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 1999; 154; 981-986.
36. Diaz LK, Gupta R, Kidwai N, Sneige N, Wiley EL. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J. Histochem. Cytochem. 2004; 52; 501-507.
37. Kay E, O'Grady A, Morgan M, Wozniak S, Jasani B. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J. Clin. Pathol. 2004; 57; 1140-1144.